New on Yahoo
Yahoo Finance
Yahoo FinanceThe Fight Against COVID19
23.83k followers • 13 symbols Watchlist by TREA
Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.
Curated by TREA
Performance
| Watchlist | Change Today | 1 Month Return | 1 Year Return | Total Return |
|---|---|---|---|---|
| The Fight Against COVID19 | +0.29% | - | - | - |
| ^GSPC | +1.60% | +0.89% | +20.69% | +5839.46% |
13 Symbols
| Symbol | Company Name | Last Price | Change | % Change | Market Time | Volume | Avg Vol (3 month) | Market Cap |
|---|---|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | 159.695 | -1.63 | -1.01% | 12:09 PM EDT | 1.75M | 7.26M | 384.42B |
| ABBV | AbbVie Inc. | 186.06 | -0.72 | -0.39% | 12:09 PM EDT | 1.57M | 5.46M | 328.56B |
| PFE | Pfizer Inc. | 31 | -0.39 | -1.24% | 12:09 PM EDT | 15.53M | 37.57M | 175.66B |
| SNY | Sanofi | 51.68 | -0.01 | -0.02% | 12:08 PM EDT | 544.68k | 2.33M | 130.25B |
| REGN | Regeneron Pharmaceuticals, Inc. | 1084.17 | +6.37 | +0.59% | 12:07 PM EDT | 122.66k | 432.04k | 119.46B |
| GILD | Gilead Sciences, Inc. | 77.2 | -0.85 | -1.09% | 12:09 PM EDT | 1.52M | 7.38M | 96.18B |
| GSK | GSK plc | 38.8528 | -0.92 | -2.31% | 12:09 PM EDT | 2.25M | 3.62M | 79.82B |
| MRNA | Moderna, Inc. | 120.91 | +2.07 | +1.74% | 12:09 PM EDT | 1.00M | 3.92M | 47.64B |
| TAK | Takeda Pharmaceutical Company Limited | 13.69 | +0.04 | +0.29% | 12:09 PM EDT | 2.24M | 1.81M | 44.37B |
| BNTX | BioNTech SE | 86.1 | -0.64 | -0.74% | 12:07 PM EDT | 145.52k | 731.41k | 20.75B |
| NVAX | Novavax, Inc. | 12.735 | +0.53 | +4.39% | 12:09 PM EDT | 4.17M | 17.44M | 1.88B |
| VIR | Vir Biotechnology, Inc. | 10.29 | +0.15 | +1.48% | 12:09 PM EDT | 143.68k | 1.16M | 1.45B |
| INO | Inovio Pharmaceuticals, Inc. | 10.55 | +0.04 | +0.38% | 12:08 PM EDT | 40.52k | 382.72k | 273.36M |
- Yahoo Finance Video
Novavax stock plunges after JPMorgan downgrade
Novavax (NVAX) shares are falling after JPMorgan downgraded the stock from Neutral to Underweight. Since May, shares surged 250% after the company announced a strategic partnership with Sanofi (SNY). Market Domination hosts Josh Lipton and Julie Hyman discuss the factors behind the call. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This article was written by Gabriel Roy
BenzingaBritish Pharma Giant GSK's Blockbuster Shingles And Respiratory Syncytial Virus Vaccine Q2 Sales Miss Expectations, Cuts Annual Vaccine Revenue Guidance
Wednesday, GSK Plc (NYSE:GSK) reported second-quarter sales of $9.95 billion (7.88 billion Sterling Pounds), up 10% year-over-year and 13% on constant currency. The analysts estimated sales of $9.66 billion. Vaccines’ sales decreased 1% at constant currency to 1.99 billion pounds, reflecting increased demand for Meningitis vaccines and uptake of Arexvy in the U.S. in line with expected waning seasonal demand. Shingrix sales reached 832 million pounds, down 4% at constant currency, with Arexvy sa
Pharmaceutical TechnologyRevenue growth for 13 of top 20 biopharmas with obesity drug successes in 2023
Six out of the top 20 companies achieved YoY operating profit growth in 2023, with those reporting greater than 20% operating profit growth.